Abstract: Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it.

Abstract: The present invention declares a pharmaceutical extract, composition that has effect to treat drug addiction, and its preparation method and quality control method. This extract is extracted from Radix Stephaniae Epigaeae. Starting medicine material of said composition is Radix Ginseng, Radix Astragali, Rhizoma Corydalis, Radix Angelicae Sinensis and Radix Ophiopogonis; and said composition also can prepared by ethanol extract of Radix Ginseng, ethanol extract of Radix Angelicae Sinensis, total alkaloids of Radix Stephaniae Epigaeae, water extract of Radix Astragali and water extract of Radix Ophiopogonis. Quality control method of said pharmaceutical composition includes one of or several of identifications and content determinations. The present invention also declares the use of said pharmaceutical extract, composition in the preparation of a medicine to treat drug addiction.

Abstract: Provided are antigenic determinants recognized by anti-human death receptor DR5 monoclonal antibody AD5-10, derivatives and uses thereof. The antigenic determinants have the amino acid sequence of LITQQDLAPAARA, wherein the core polypeptide is QDLAP. The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants and derivatives thereof can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine. Their nucleotide encoding sequences can be used for preparing antisense nucleotides and small molecular ribonucleotides for treating and preventing tumor and/or AIDS and the like.

Abstract: The invention relates to a method for preparing polyepitope chimeric gene vaccines, designated as Epitopes Assemble Library Immunization (EALI). It involves the construction of expression libraries of polyepitope chimeric genes with different sizes and lengths using gene shuffling and random assembly so as to screen polyepitope chimeric gene vaccines. Immunization of the body with the gene libraries of the invention results in the induction of high level of specific antibodies and specific types of cytokines, and protection on the body.

Abstract: The present invention discloses a monoclonal antibody against the extracellular domain of human tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 (death receptor 5). The present invention also provides a method of producing the monoclonal antibody, amino acid sequences of the variable regions of the monoclonal antibody's heavy chain and light chain, as well as use of the monoclonal antibody for preparation of a medicament in the treatment of various cancers and/or AIDS.

Abstract: Fusion proteins of recombinant SARS coronavirus structural proteins, their production and uses are provided. An optimized SARS coronavirus S protein gene which can be highly expressed in the mammalian cell strains and SARS coronavirus S protein variants comprising deletion, modification or mutation amino acids 318-510 corresponding to SARS coronavirus S protein are also provided.

Abstract: The invention relates to a method for preparing polyepitope chimeric gene vaccines, designated as Epitopes Assemble Library Immunization (EALI). It involves the construction of expression libraries of polyepitope chimeric genes with different sizes and lengths using gene shuffling and random assembly so as to screen polyepitope chimeric gene vaccines. Immunization of the body with the gene libraries of the invention results in the induction of high level of specific antibodies and specific types of cytokines, and protection on the body.